Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice

Tang,Y.,Yan,M.,Fang,Z.,Jin,S.,Xu,T.

DOI: https://doi.org/10.1136/bmjdrc-2023-003837

2024-05-08

BMJ Open Diabetes Research & Care

Abstract:Introduction There has been increasing evidence that the gut microbiota is closely related to type 2 diabetes (T2D). Metformin (Met) is often used in combination with saxagliptin (Sax) and repaglinide (Rep) for the treatment of T2D. However, little is known about the effects of these combination agents on gut microbiota in T2D. Research design and methods A T2D mouse model induced by a high-fat diet (HFD) and streptozotocin (STZ) was employed. The T2D mice were randomly divided into six groups, including sham, Met, Sax, Rep, Met+Sax and Met+Rep, for 4 weeks. Fasting blood glucose level, serum biochemical index, H&E staining of liver, Oil red O staining of liver and microbiota analysis by 16s sequencing were used to access the microbiota in the fecal samples. Results These antidiabetics effectively prevented the development of HFD/STZ-induced high blood glucose, and the combination treatment had a better effect in inhibiting lipid accumulation. All these dosing regimens restored the decreasing ratio of the phylum Bacteroidetes: Firmicutes, and increasing abundance of phylum Desulfobacterota, expect for Met. At the genus level, the antidiabetics restored the decreasing abundance of Muribaculaceae in T2D mice, but when Met was combined with Rep or Sax, the abundance of Muribaculaceae was decreased. The combined treatment could restore the reduced abundance of Prevotellaceae_UCG-001, while Met monotherapy had no such effect. In addition, the reduced Lachnospiraceae_NK4A136_group was well restored in the combination treatment groups, and the effect was much greater than that in the corresponding monotherapy group. Therefore, these dosing regimens exerted different effects on the composition of gut microbiota, which might be associated with the effect on T2D. Conclusions Supplementation with specific probiotics may further improve the hypoglycemic effects of antidiabetics and be helpful for the development of new therapeutic drugs for T2D.

endocrinology & metabolism

What problem does this paper attempt to address?

The paper aims to explore the effects of metformin, saxagliptin, and repaglinide, either alone or in combination, on the gut microbiota of mice with type 2 diabetes induced by a high-fat diet/streptozotocin (HFD/STZ). Specifically, the study establishes a type 2 diabetes mouse model and randomly divides these mice into six groups for different drug treatments to evaluate whether these antidiabetic drugs can improve diabetes-related symptoms such as hyperglycemia, liver damage, and lipid accumulation. Additionally, the study analyzes the impact of these drugs on the composition and diversity of the gut microbiota. The research found that these drugs and their combination treatments effectively prevent and alleviate HFD/STZ-induced hyperglycemia, with combination treatments being more effective in inhibiting lipid accumulation. Furthermore, drug treatments affected the abundance of specific gut microbes, particularly increasing the ratio of Bacteroidetes to Firmicutes, which may be related to the mechanisms of action of the antidiabetic drugs. Therefore, the study provides a reference for developing new treatments for type 2 diabetes and suggests that supplementing specific probiotics may further enhance the hypoglycemic effect.